Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorQueen Mary Hospital, Hong Kong
About this trial
To assess the clinical efficacy of add-on topical timolol 0.5% eye drops to betamethasone valerate 0.1% for the treatment of EGFR-TKI and ALK-TKI induced paronychia.
Eligibility criteria
Qualifiers
Aged 18 years or above, either males or females.
Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.
Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use
Written informed consent obtained from patient
Disqualifiers
1. Age below18
2. Patients who are allergic to, or contraindicated to topical timolol use
3. Pregnant women or nursing mother
4. Non-consenting patients
Trial design
Treatments tested in this trial
- Timolol 0.5% eye drops and betamethasone valerate 0.1% cream
- Betamethasone valerate 0.1% cream
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov